Γ

SynBioBeta Speaker

Gideon Lapidoth

Enzymit

CEO & Co-founder

I am the CEO & Co-Founder of Enzymit, where I lead strategy, partnerships, and company building around a cell-free biomanufacturing platform. Enzymit combines computational enzyme design, deep learning, and high-throughput discovery to develop controllable production systems for complex molecules.I hold a PhD in Computational Protein Design from the Weizmann Institute of Science and completed postdoctoral research in enzyme engineering under Prof. Dan Tawfik. At Enzymit, we have advanced the platform to kilogram-scale validation in hyaluronic acid production with industrial partners, and we are now focused on collaborations around industrial biotechnology, advanced biomanufacturing, scale-up, and commercialization of next-generation production technologies.

Sessions Featuring

Gideon

This Year

Lightning Talk

11:31 AM

-

11:35 AM

Biomanufacturing

Building the Next Production System for Molecules

The world does not have a feedstock problem. It has a transformation problem. Many of the molecules modern industry depends on are still too difficult, too inconsistent, or too expensive to manufacture at scale. Enzymit is building a new production system based on AI-designed enzymes and cell-free manufacturing, combining the selectivity of biology with the control of industrial processing. We have proven this first in hyaluronic acid, where molecular precision directly affects product performance and manufacturing value. Hyaluronic acid is the wedge. The broader opportunity is to establish cell-free manufacturing as a foundational production layer for the carbon economy.

Lightning Talk

11:31 AM

-

11:35 AM

Biomanufacturing

Building the Next Production System for Molecules

The world does not have a feedstock problem. It has a transformation problem. Many of the molecules modern industry depends on are still too difficult, too inconsistent, or too expensive to manufacture at scale. Enzymit is building a new production system based on AI-designed enzymes and cell-free manufacturing, combining the selectivity of biology with the control of industrial processing. We have proven this first in hyaluronic acid, where molecular precision directly affects product performance and manufacturing value. Hyaluronic acid is the wedge. The broader opportunity is to establish cell-free manufacturing as a foundational production layer for the carbon economy.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include